Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech VC Funds in Europe

Last updated: Apr 2024 A list of 50 VC funds that invest in Biotech startups based in Europe. We rank investors based on the number of investments they made in Biotech companies from Europe. We update this investor list every month.

Top 50 Biotech VC Funds in Europe

Investor	Biotech Europe investments
Sofinnova Partners	60
UK Innovation & Science Seed Fund	52
Bpifrance	49
Parkwalk Advisors	41
HTGF \| High-Tech Gruenderfonds	40
Novo Holdings	38
Oxford Science Enterprises	34
Oxford Technology Management	34
Oxford Capital	33
Scottish Investment Bank	33
Scottish Enterprise	33
Kurma Partners	31
Enterprise Ireland	29
Catapult Ventures	28
Seventure Partners	28
Boehringer Ingelheim Venture Fund	27
Mercia Fund Managers	26
GO CAPITAL	26
BioInnovation Institute	24
Epidarex Capital	23
Karista	22
Auriga Partners	22
Oxford Science Enterprises	22
MIG Capital	21
Archangels	21
AlbionVC	20
Omnes Capital	20
Development Bank of Wales	20
Idinvest Partners	20
M Ventures	20
Centre for the Development of Industrial Technology (CDTI)	20
Future Planet Capital	19
Caixa Capital Risc	19
GM&C Life Sciences Fund	19
Deepbridge Capital	19
Newable Private Investing	18
IP Group	18
HealthCap	18
Forbion Capital Partners	17
Kelvin Capital	17
Elaia	17
AdBio partners	16
Wellcome Trust	16
TRICAPITAL	16
Meusinvest (Noshaq)	16
Ysios Capital	15
NRW.BANK	15
EQT Life Sciences	15
Cambridge Angels group	15
Kernel Capital	15

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
Oxford Space Systems — Oxford Space Systems is a multi-award-winning, record-breaking venture capital backed, space tech business that's developing a new generation of deployable antennas and space structures for the global satellite industry. Using both innovative design techniques such as origami and novel proprietary materials developed by the company, OSS'structures are lighter, less complex and lower cost than alternatives in commercial demand. Founded in late 2013, OSS set a record for the space sector with it's AstroTube Boom: the fastest development of a new product from concept to successful deployment on orbit in under 30 months. Today, the 18 strong and growing OSS team is a diverse mix of international graduates and experienced space industry professionals, with over 100 years of combined space sector experience. OSS investors include a small syndicate of UK venture capital funds together US based investors, Space Angels. Oxford Space Systems has successfully completed a number of UK government supported co-developments with leading European satellite builders as well straight commercial contracts in both Asia and the US. As part of its planned expansion, OSS move into its own custom facility at the Harwell Space Cluster in August 2018, giving it the largest clean room at the cluster. The facility will meet required security standards to undertake UK government defense & security contracts. .
Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

HawkCell — A plug-and-play solution turning human MRI into the first animal-dedicated imaging enhanced with AI algorithms. A unique MRI solution.
Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.
Docent — Docent is the first AI-powered mobile application to offer a fully-personalized experience for discovering, accessing and collecting contemporary masterpieces.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
Adsilico — Adsilico redefines medical device innovation.
Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Graswald — Graswald engages in the creation of natural and digital 3D worlds for the entertainment industry.
CustomSurg — RETHINKING TRAUMA SURGERY At CustomSurg we are changing the treatment of complex bone fractures from a subjective to an objective approach, through personalized solutions.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Revagenix — Game-changing approach to anti-infectives
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Claris Biotherapeutics — Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

Oxford Sciences Innovation is the world’s largest university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companiestaking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Finland

Portfolio highlights

Navenio — Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England.
Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Mobile, Health Care
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Scan.com — Use scan.com to find the best medical imaging centers near you Find an MRI scan, CT scan, X-ray Scan, or other diagnostic imaging scan with scan.com.
HelloSelf — The UK's Trusted Online Private Clinical Therapy Service
TextMine — Legislate is an easy-to-use contract management platform which provides a suite of customisable contracts for businesses and landlords.

Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Itza — Itza offers digital learning media and technology business focused on teens.
ilosta — Ilosta specializes in developing novel technology to reduce the cost, time, and dangers associated with monitoring the health of engineering structures and extending their lifespan without requiring human intervention.
QuickBlock — Interlocking blocks is the best way to summarise how QUICKBLOCK works to a novice. Our interlocking blocks click together to build desired structures.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Series B, Seed
France, Spain, Switzerland

Portfolio highlights

Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Lative — Lative automates capacity planning, maximizing profitable sales growth & revenue efficiency for high-performance revenue teams.
Cytidel — Cytidel helps security teams reduce breaches, save time, and stay secure. Vulnerability Management and Cyber Risk Management, and Threat Intelligence Specialists
Positive Carbon — Positive Carbon provides an innovative solution for businesses to track, manage, and reduce food waste. With real-time analytics, CO2 calculation, and a comprehensive learning platform, we help you save costs and achieve sustainability goals. Request a demo today to start making a positive environmental impact.

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
Urban Machine — Urban Machine pioneers sustainable wood reclamation. The Machine leverages robotics and AI technology to transform the construction industry by reducing wood waste and promoting circular practices.
Pencil Biosciences — Next Generation Genome Editing Tool

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee engagement surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

GO CAPITAL is a management company approved by the AMF and a member of AFIC. It is based in Rennes, and manages more than 130 million of assets by investing primarily in western France in innovative companies with high growth potential.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series A
France, Canada, Israel

Portfolio highlights

Genevos — Genevos specializes in integrating hydrogen and fuel cell systems in the maritime industry.
Biosency — BIOSENCY is a medical device company focused on developing smart healthcare solutions. Our first product, a connected PPG sensor system using smart data is a monitoring and prevention solution dedicated to respiratory insufficiency. Our company is based in Rennes, France. We work closely with doctors and researchers to bring to the medicalcommunity the best possible tools to help patients.
Sweetch Energy — Sweetch Energy is created to leverage most recent academic discoveries in nanotechnologies and materials in the blue osmotic energy field and combined them with the efficiency of the private sector.

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.
Solid Therapeutics — SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
Nyra Medical — MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Investment focus

Software, Biotechnology, Health Care
Seed, Series A, Series B
France, United States, Germany

Portfolio highlights

constellr — Smart Farming and Climate Monitoring from Space. At constellr, we are using cutting-edge beyond-visual imaging technology to revolutionise the way we assess crucial aspects of our planet's health.
Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Kranus Health — Kranus Health is a global provider for Men‘s Health Prescription Digital Therapeutics (PDTs). Our therapies make millions of men live a better and longer life and enable doctors to treat their patients more efficiently.

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
France, United States, Switzerland

Portfolio highlights

Patrowl — Identify and harden your External Security Posture with the leader. Let us manage time-consuming tasks and focus on remediation
Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.
Vade Secure — Vade is a global leader in predictive email defense, protecting 1 billion inboxes worldwide. AI-based email security for Microsoft 365.

Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

Archangel Lightworks — Archangel Lightworks is integrating space and air assets using laser communication.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
Quantum Motion — One Hundred Qubits is Interesting. One Million is World-changing

Zusammen gestalten wir die Unternehmen von morgen.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Funding Round, Series B
Germany, Austria, Canada

Portfolio highlights

AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
HawkCell — A plug-and-play solution turning human MRI into the first animal-dedicated imaging enhanced with AI algorithms. A unique MRI solution.
Look Up Space — Lookup space is the next global leader for space safety, security and sustainability

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Information Technology
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

kennek — Connected infrastructure for loans & credits
Accelex — Accelex Technology, the technology solution to automate the acquisition, analysis and reporting of critical investment data. Learn more today.
OpenDialog AI — OpenDialog is the only conversational AI automation software to safely harness the most advanced Generative AI & LLMs in regulated sectors.

Omnes, "Powering Entrepreneurs" is a Leading private equity firm dedicated to energy transition and innovation.

Investment focus

Software, Biotechnology, Health Care
Series A, Funding Round, Series B
France, United States, Belgium

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Quandela — Quandela is an expert in the fabrication of performing devices for the research in quantum photonics and quantum information. They fabricate unique solid-state sources of quantum light. These sources bring a new revolution in quantum technologies based on light.The company's single-photon source device combines photonics and semiconductorquantum dots for quantum communication, computation and sensing and permits to collect the emitted single-photons with exceptional efficiency at high rates, enabling researchers to strongly reduce the charge noise decoherence and assist in the emission of identical photons with fidelity close to unity, an essential requirement for the development of the most advanced quantum applications.
Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Bikmo — Bikmo exists to enable you to ride more.We build awesome insurance products to protect our customers for unexpected events, use technology to make taking out and managing your policy ultra-simple, and provide exceptional customer experiences through our team of bike geeks.We’re now 5 years into our mission to enable anyone, anywhere, to protecttheir lifestyle, so they can spend more time enjoying it. And, become the brand that resonates with and protects the passion and drive behind the bike and adventure sports community.At the heart of our business is a bunch of bike and adventure sports geeks who choose to spend their free time in the epic wild places our earth has to offer and we want to continue to be able to do just that.
Hope Macy — Hope Macy is a dynamic and expanding financial technology company. Its primary focus is on consumers who require additional security in managing their money, as well as those in the subprime sector.
Validient — Digitally automated compliance and due diligence solutions. Empower your business with the ultimate advantage.

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Software, Health Care
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
BreezoMeter — BreezoMeter offers personalized air quality & pollen data as well as active fire alerts with worldwide coverage & accuracy down to the street level.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Grant
Spain, United States, France

Portfolio highlights

Ailin — Ailin offers digital health monitoring solutions with home self-sampling kits analyzed by Clínica Universidad de Navarra.
Affirma Biotech — Affirma Biotech develops new orally available immunotherapeutic drugs for the treatment of severe infections and cancer
KUMUX — Next generation smart-light devices

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Singapore

Portfolio highlights

Captura — Captura mission is globally scalable carbon capture to support a sustainable future for the climate.
Regent — We build all-electric, passenger-carrying, wing-in-ground-effect vehicles to service coastal routes with technology available today.
Pencil Biosciences — Next Generation Genome Editing Tool

Caixa Capital Risc (CCR) is the VC arm of CriteriaCaixa which invests in innovative companies in their start-up and growth stages. The company has three specialised teams in the areas of Information Technology, Life Sciences, and Industrial technologies. Caixa Capital Risc currently manages more than €300m through 11 specialised vehicles.

Investment focus

Software, Biotechnology, E-Commerce
Seed, Funding Round, Series A
Spain, United States, United Kingdom

Portfolio highlights

inari — INARI provides blockchain, machine learning and artificial intelligence technologies for the Insurance industry
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Mobile Media Content - TICKETING3D — Mobile Media Content, a Barcelona, Spain-based provider of virtual visualization technologies, raised €400k in seed funding.Founded in May 2012 by Michele Marino, CEO and Francis Casado, Head of Business Development, Mobile Media Content provides TICKETING3D, a SaaS 3D seating chart of a venue, which allows the final user to check the view fromhis seat before purchasing a ticket. It also Tranfer3D, which lets any club or sports organization to move supporters or fans from one location to another, and Match3D, a 2nd screening tool that allows following matches in real time.The company currently employs 20 people

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

Circada — Innovative Circadian lighting reconnects the body clock with nature
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Deep Render — Deep Render Ltd. is a spin-out from the Department of Computing at Imperial College London. We are a London based AI start-up that is developing the next generation of media compression algorithms. Our proprietary and patented technology is at the forefront of machine learning research. Furthermore, our Biological Image Compression results arestate-of-the-art, providing at least a 50% efficiency gain over the previous standards
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

novosound — Novosound is an award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
Snappy Shopper — Order your favourite products from your local convenience store, for delivery from as little as 30 minutes with Snappy Shopper. Your every day essentials are only a click away - order your grocery delivery online or through our app.
Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.

Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Series B
France, United States, Spain

Portfolio highlights

AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
Vibe — Advertise your brand on CTV & OTT content with Vibe's self-serve ad platform to target hundreds of channels & networks and reach millions of households.
Composable Prompts — Composable Prompts helps enterprises deploy LLM technology, with governance, collaboration, orchestration, and a unique virtualization engine.

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Astraveus — Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies.
Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
Anoat Therapeutics — Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series B
United Kingdom, France

Portfolio highlights

ŌGI Bio — Offering an affordable route to automating routine microbial culturing with a unique, modular, retrofittable device
Sellmyartworks — SellmyArtworks is to buy and sell pre-loved artwork in a simple, fast, and affordable way like no other pre-owned art seller.
Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality

Noshaq offers financial services to help businesses develop.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Samabriva — Biotechnology company that has developed an automated, proprietary bioproduction system available to companies who want to produce high-value molecules.
Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.
HEPHAISTOS-Pharma — Hephaistos Pharma is a developing weapons firm. They provide services for oncology, immunotherapy, and cancer. An online inquiry form is available on the company's website.

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Spain, United States, Switzerland

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Investment focus

Biotechnology, Software, Information Technology
Seed, Series A, Series B
Germany, United States

Portfolio highlights

widu — widu enables real estate and accommodation companies to source visuals (photography, video, drone) at scale through its serviced marketplace
bNear — bNear is the digital space for all distributed- & hybrid teams - Safe and convenient in Microsoft Teams!
Companyon Analytics — Companyon Analytics provides data security, cloud infrastructure, information technology, technical solutions, and consultancy services.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Estonia

Portfolio highlights

zeroRISC — ZeroRISC operates as a stealth start-up making hardware security foundations transparent and trustworthy.
Albotherm — Smart transitioning coating technology - A bright idea for shade.
Five Alarm Bio — Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
Ireland, United Kingdom, France

Portfolio highlights

Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.
Causeway Sensors — The Affinity, is a compact, bench-top Biosensor providing accurate real-time analysis at an accessible price. The Affinity biosensor and accompanying Access Chip incorporate the latest advancements in Nanotechnology, providing the biochemistry researcher the perfect platform to explore the complex world of biomolecular interactions.

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate